首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1427879

2024 年癌症診斷液體活體組織切片全球市場報告

Liquid Biopsy For Cancer Diagnostics Global Market Report 2024

出版日期: 按訂單生產 | 出版商:

The Business Research Company | 英文 175 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄

用於癌症診斷的液體活體組織切片的市場規模預計在未來幾年將快速成長。預計到 2028 年將以 15.7% 的複合年成長率 (CAGR) 成長至 164.2 億美元。預測期內的預期成長是由於將液體活體組織切片涵蓋常規癌症診斷、廣泛普及液體活體組織切片進行癌症早期檢測、擴大癌症篩檢計劃以及腫瘤學中的個性化醫療而推動的。重點關注衛生保健系統和加強衛生系統。液體活體組織切片研究經費。預測期內的顯著趨勢包括多組體學液體活體組織切片方法的興起、人工智慧與液體活體組織切片分析的整合、液體活體組織切片應用擴展到腫瘤學之外、基於血液的癌症生物標記的開發以及某些類型的液體活體組織切片檢測癌症。

癌症發生率的預期增加預計將推動未來癌症診斷液體活體組織切片市場的擴大。癌症包括出現在不同器官和組織中的多種疾病，是由於異常細胞不受控制地生長而導致的，這些細胞突破正常邊界，可以轉移到其他器官或侵入鄰近的身體部位。有性別。癌症盛行率的增加需要診斷程序，例如癌症和腫瘤復發的早期檢測、個人化風險評估和持續治療監測。液體活體組織切片已成為一種關鍵工具，透過從轉移性或原發性腫瘤部位捕獲癌細胞或其產物，提供對疾病的全面、即時的了解。該方法提供了有關癌細胞進化、治療標靶和抗治療性機制的寶貴資訊。 2021年，美國癌症協會報告稱，2020年將有180萬人新診斷出罹患癌症。此外，美國國家癌症研究所發布的2020年9月資料顯示，美國新增癌症患者數量大幅增加，2020年達到1,806,590人，創近43年來創紀錄的43萬人。與去年相比，男性診斷病例增加百分比。

對個人化醫療不斷成長的需求預計將推動癌症診斷液體活體組織切片市場的發展。個人化醫療代表了一種創新的醫療保健方法，它考慮了患者基因、環境和生活方式的個體差異。液體活體組織切片在識別與癌症相關的特定基因突變和生物標記方面發揮著重要作用，有助於制定量身定做的標靶治療策略。值得注意的是，2022 年個人化醫療聯盟報告稱，2021 年新核准的新型分子實體 (NME) 中有 35% 是個人化醫療。個人化醫療需求的激增預計將在可預見的未來推動生物資訊服務市場的成長。

全球癌症診斷液體活體組織切片市場，按類型細分、實際和預測，2018-2023、2023-2028、2033
產品
服務
全球癌症診斷活體組織切片市場、按樣本細分、績效和預測，2018-2023、2023-2028、2033
血
尿
唾液
全球癌症診斷液體活體組織切片市場、按癌症細分、績效和預測，2018-2023、2023-2028、2033
肺癌
乳癌
結腸癌
其他癌症
全球癌症診斷活體組織切片市場，按最終用戶細分，實際和預測，2018-2023、2023-2028、2033
醫院
診斷中心
其他最終用戶

第 7 章區域與國家分析

全球癌症診斷液體活體組織切片市場，按地區、績效和預測，2018-2023年、2023-2028年、2033年
全球癌症診斷液體活體組織切片市場，按國家、績效和預測，2018-2023年、2023-2028年、2033年

第8章亞太市場

第9章中國市場

第10章印度市場

第11章日本市場

第12章澳洲市場

第13章印尼市場

第14章韓國市場

第15章西歐市場

第16章英國市場

第17章德國市場

第18章法國市場

第19章義大利市場

第20章西班牙市場

第21章東歐市場

第22章俄羅斯市場

第23章北美市場

第24章美國市場

第25章加拿大市場

第26章南美洲市場

第27章巴西市場

第28章中東市場

第29章非洲市場

第30章競爭形勢及公司概況

癌症診斷液體活體組織切片市場競爭形勢
癌症診斷市場液體活體組織切片公司簡介
- F. Hoffman La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc.
- Illumina Inc.
- The Menarini Group

第31章其他大型創新公司

Bio-Rad Laboratories Inc.
QIAGEN Inc.
Exact Sciences Corporation
Bio-Techne Corporation
ArcherDX Inc.
Neogenomics Laboratories Inc.
Guardant Health Inc.
Myriad Genetics Inc.
Foundation Medicine Inc.
Amoy Diagnostics Co. Ltd.
Biocartis Group NV
Biodesix Inc.
MDx Health Inc.
Sysmex Inostics Inc.
Biocept Inc.

第32章競爭基準化分析

第 33 章. 競爭對手儀表板

第34章重大併購

第35章未來前景與可能性分析

第36章附錄

簡介目錄

Product Code: r13723

Liquid biopsy for cancer diagnostics offers a less invasive alternative to traditional tissue biopsies, involving the assessment of genetic material or biomarkers found in a patient's blood or other bodily fluids to detect and monitor the presence of cancer. This approach is commonly utilized for screening and identifying non-small cell lung cancer (NSCLC) and is also employed as a gastrointestinal and ovarian liquid biopsy for cancer diagnostics.

The main categories within liquid biopsy for cancer diagnostics encompass products and services. Products refer to procedures, methods, or tools designed or utilized for identifying illnesses or diseases in humans or other vertebrate animals. Various types of samples, such as blood, urine, and saliva, are utilized in this diagnostic approach. Liquid biopsy for cancer diagnostics is applicable to various types of cancer, including lung cancer, breast cancer, colon cancer, and others. The end-users for these diagnostics include hospitals, diagnostic centers, and other healthcare institutions.

The liquid biopsy for cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides liquid biopsy for cancer diagnostics market statistics, including liquid biopsy for cancer diagnostics industry global market size, regional shares, competitors with a liquid biopsy for cancer diagnostics market share, detailed liquid biopsy for cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liquid biopsy for cancer diagnostics industry. This liquid biopsy for cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liquid biopsy for cancer diagnostics market size has grown rapidly in recent years. It will grow from $7.82 billion in 2023 to $9.17 billion in 2024 at a compound annual growth rate (CAGR) of 17.3%. The growth experienced in the past can be ascribed to progress in genomic research, heightened recognition of the advantages of liquid biopsy, a surge in cancer prevalence, an uptick in the demand for non-invasive cancer testing, and the expansion of precision medicine initiatives.

The liquid biopsy for cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $16.42 billion in 2028 at a compound annual growth rate (CAGR) of 15.7%. Anticipated growth during the forecast period is expected to result from the incorporation of liquid biopsy into routine cancer diagnostics, the widespread adoption of liquid biopsy for early cancer detection, the expansion of cancer screening programs, an increased emphasis on personalized medicine in oncology, and augmented funding for liquid biopsy research. Noteworthy trends in the forecast period encompass the rise of multi-omics liquid biopsy approaches, the integration of artificial intelligence into liquid biopsy analysis, the extension of liquid biopsy applications beyond oncology, the development of blood-based biomarkers for cancer, and the tailoring of liquid biopsy assays for specific cancer types.

The projected increase in cancer incidence is anticipated to drive the expansion of the liquid biopsy for cancer diagnostics market in the future. Cancer, encompassing a wide range of illnesses that can manifest in various organs or tissues, results from the uncontrolled proliferation of aberrant cells that breach normal boundaries, potentially spreading to other organs or invading adjacent body parts. The heightened prevalence of cancer necessitates diagnostic procedures, including early cancer or tumor recurrence detection, individualized risk assessment, and ongoing therapy monitoring. Liquid biopsy emerges as a pivotal tool, offering comprehensive and real-time insights into the disease by capturing tumor cells or their products from metastatic or primary tumor sites. This method provides valuable information on tumor cell evolution, therapeutic targets, and mechanisms of therapy resistance. In 2021, the American Cancer Society reported 1.8 million new cancer cases diagnosed in 2020. Additionally, data from September 2020 published by the National Cancer Institute indicated a significant increase in new cancer cases in the United States, reaching 1,806,590 in 2020, marking a 43% rise in cases diagnosed in men compared to the previous year.

The growing demand for personalized medicine is poised to fuel the advancement of the liquid biopsy for cancer diagnostics market. Personalized medicine represents an innovative healthcare approach that considers individual variabilities in patients' genes, environments, and lifestyles. Liquid biopsy plays a crucial role in identifying specific genetic mutations and biomarkers associated with cancer, facilitating the development of tailored and targeted treatment strategies. Notably, in 2022, the Personalized Medicine Coalition reported that personalized medicines accounted for 35% of newly approved new molecular entities (NMEs) in 2021. This surge in demand for personalized medicine is expected to drive the growth of the bioinformatics services market in the foreseeable future.

A prominent trend gaining traction is the focus on product innovations by major companies. These companies are strategically investing in the development of cutting-edge products to bolster their market position. An exemplar of this trend is BostonGene, a US-based biomedical software company, which introduced new liquid biopsy solutions in June 2023. These solutions aim to identify clinically relevant gene alterations, expanding the test portfolio and accelerating the development of novel assays, analytical tools, and pipelines. The innovative approach involves leveraging artificial intelligence-driven molecular and immunological profiling methodologies to analyze tumors, microenvironments, and host immunity. Notably, these solutions support immunotherapy treatment, provide insights into a patient's immune-related disorders, and enable the monitoring of disease progression and response to treatment.

Major players in the liquid biopsy for cancer diagnostics market are directing their efforts toward the development of advanced liquid biopsy assays. These assays, characterized by sophistication and refinement, analyze various components within liquid biological samples, such as blood or other bodily fluids. The objective is to detect and characterize specific biomarkers associated with cancer or other diseases. Illumina Inc., a global leader in DNA sequencing, exemplifies this focus on innovation. In November 2023, the company announced the launch of the 'TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)' research assay. This assay facilitates noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) extracted from blood. Designed to streamline integration for users, the TSO 500 ctDNA v2 assay enhances the depth of insights available for cancer research.

In January 2022, when Exact Sciences Corp., a US-based molecular diagnostics company, acquired Thrive Earlier Detection Corp. for $2.15 billion. This strategic acquisition positions Exact Sciences Corp. to access clinical and regulatory teams, scale laboratory and IT capabilities, and advance blood-based, multi-cancer screening, aligning with evolving norms in cancer treatment. Thrive Earlier Detection Corp., known for its expertise in producing liquid biopsy tests, focuses on the early detection of multiple cancers.

Major companies operating in the liquid biopsy for cancer diagnostics market report are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liquid biopsy for cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liquid biopsy for cancer diagnostics market includes revenues earned by entities by providing tumor detection, test validation, and clinical utility. The market value includes the value of related goods sold by the service provider or included within the service offering. The liquid biopsy for cancer diagnostics markets also include sales of instruments, reagent kits, and liquid biopsy kits, which are used in providing liquid biopsy services. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liquid Biopsy For Cancer Diagnostics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liquid biopsy for cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liquid biopsy for cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liquid biopsy for cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Product; Services
2) By Sample: Blood; Urine; Saliva
3) By Cancer: Lung Cancer; Breast Cancer; Colon Cancer; Other Cancers
4) By End-User: Hospitals; Diagnostic Centers; Other End-Users
Companies Mentioned: F. Hoffman La Roche Ltd.; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Illumina Inc.; The Menarini Group
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

1. Executive Summary

2. Liquid Biopsy For Cancer Diagnostics Market Characteristics

3. Liquid Biopsy For Cancer Diagnostics Market Trends And Strategies

4. Liquid Biopsy For Cancer Diagnostics Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Liquid Biopsy For Cancer Diagnostics Market Size and Growth

5.1. Global Liquid Biopsy For Cancer Diagnostics Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Liquid Biopsy For Cancer Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Liquid Biopsy For Cancer Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Liquid Biopsy For Cancer Diagnostics Market Segmentation

6.1. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Product
Services
6.2. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Blood
Urine
Saliva
6.3. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Lung Cancer
Breast Cancer
Colon Cancer
Other Cancers
6.4. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Diagnostic Centers
Other End-Users

7. Liquid Biopsy For Cancer Diagnostics Market Regional And Country Analysis

7.1. Global Liquid Biopsy For Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Liquid Biopsy For Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market

8.1. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Liquid Biopsy For Cancer Diagnostics Market

9.1. China Liquid Biopsy For Cancer Diagnostics Market Overview
9.2. China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Liquid Biopsy For Cancer Diagnostics Market

10.1. India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Liquid Biopsy For Cancer Diagnostics Market

11.1. Japan Liquid Biopsy For Cancer Diagnostics Market Overview
11.2. Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Liquid Biopsy For Cancer Diagnostics Market

12.1. Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Liquid Biopsy For Cancer Diagnostics Market

13.1. Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Liquid Biopsy For Cancer Diagnostics Market

14.1. South Korea Liquid Biopsy For Cancer Diagnostics Market Overview
14.2. South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Liquid Biopsy For Cancer Diagnostics Market

15.1. Western Europe Liquid Biopsy For Cancer Diagnostics Market Overview
15.2. Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Liquid Biopsy For Cancer Diagnostics Market

16.1. UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Liquid Biopsy For Cancer Diagnostics Market

17.1. Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Liquid Biopsy For Cancer Diagnostics Market

18.1. France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Liquid Biopsy For Cancer Diagnostics Market

19.1. Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Liquid Biopsy For Cancer Diagnostics Market

20.1. Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market

21.1. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market Overview
21.2. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Liquid Biopsy For Cancer Diagnostics Market

22.1. Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Liquid Biopsy For Cancer Diagnostics Market

23.1. North America Liquid Biopsy For Cancer Diagnostics Market Overview
23.2. North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Liquid Biopsy For Cancer Diagnostics Market

24.1. USA Liquid Biopsy For Cancer Diagnostics Market Overview
24.2. USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Liquid Biopsy For Cancer Diagnostics Market

25.1. Canada Liquid Biopsy For Cancer Diagnostics Market Overview
25.2. Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Liquid Biopsy For Cancer Diagnostics Market

26.1. South America Liquid Biopsy For Cancer Diagnostics Market Overview
26.2. South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Liquid Biopsy For Cancer Diagnostics Market

27.1. Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Liquid Biopsy For Cancer Diagnostics Market

28.1. Middle East Liquid Biopsy For Cancer Diagnostics Market Overview
28.2. Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Liquid Biopsy For Cancer Diagnostics Market

29.1. Africa Liquid Biopsy For Cancer Diagnostics Market Overview
29.2. Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Liquid Biopsy For Cancer Diagnostics Market Competitive Landscape And Company Profiles

30.1. Liquid Biopsy For Cancer Diagnostics Market Competitive Landscape
30.2. Liquid Biopsy For Cancer Diagnostics Market Company Profiles
- 30.2.1. F. Hoffman La Roche Ltd.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Thermo Fisher Scientific Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Agilent Technologies Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Illumina Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. The Menarini Group
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Liquid Biopsy For Cancer Diagnostics Market Other Major And Innovative Companies

31.1. Bio-Rad Laboratories Inc.
31.2. QIAGEN Inc.
31.3. Exact Sciences Corporation
31.4. Bio-Techne Corporation
31.5. ArcherDX Inc.
31.6. Neogenomics Laboratories Inc.
31.7. Guardant Health Inc.
31.8. Myriad Genetics Inc.
31.9. Foundation Medicine Inc.
31.10. Amoy Diagnostics Co. Ltd.
31.11. Biocartis Group NV
31.12. Biodesix Inc.
31.13. MDx Health Inc.
31.14. Sysmex Inostics Inc.
31.15. Biocept Inc.

32. Global Liquid Biopsy For Cancer Diagnostics Market Competitive Benchmarking

33. Global Liquid Biopsy For Cancer Diagnostics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Liquid Biopsy For Cancer Diagnostics Market

35. Liquid Biopsy For Cancer Diagnostics Market Future Outlook and Potential Analysis

35.1 Liquid Biopsy For Cancer Diagnostics Market In 2028 - Countries Offering Most New Opportunities
35.2 Liquid Biopsy For Cancer Diagnostics Market In 2028 - Segments Offering Most New Opportunities
35.3 Liquid Biopsy For Cancer Diagnostics Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies